Buprenorphine-Naloxone

Generic Name: Buprenorphine-Naloxone

Brand Names: Suboxone, Zubsolv, Bunavail

Buprenorphine-naloxone is a partial opioid agonist combination used for opioid use disorder treatment. Reduces cravings and withdrawal without significant euphoria.

Addiction MedicineSubstance UseOpioidsControlled Substances

Drug Class

Partial Opioid Agonist / Opioid Antagonist Combination

DEA Schedule

Schedule Schedule III

Pregnancy

Category C — Buprenorphine-naloxone has shown adverse effects in animal reproduction studies. Buprenorphine monotherapy is generally preferred over the combination product during pregnancy because naloxone may precipitate withdrawal in an opioid-dependent fetus. Use during pregnancy only if the potential benefit justifies the potential risk.

Available Forms

Sublingual tablet (2 mg/0.5 mg, 8 mg/2 mg), Sublingual film (2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, 12 mg/3 mg), Buccal film (2.1 mg/0.3 mg, 4.2 mg/0.7 mg, 6.3 mg/1 mg)

What It's Used For

Dosage Quick Reference

These are general dosage guidelines. Your doctor will determine the appropriate dose for your specific situation.

Phase	Starting Dose	Maintenance Dose
Induction (opioid-dependent, short-acting opioids)	2 mg/0.5 mg to 4 mg/1 mg on Day 1	Titrate in 2–4 mg increments to control withdrawal symptoms
Stabilization (Days 2–7)	Adjust to suppress withdrawal and cravings	Target 8 mg/2 mg to 16 mg/4 mg per day
Long-term maintenance	16 mg/4 mg per day (typical)	4 mg/1 mg to 24 mg/6 mg per day; max 24 mg/6 mg

Side Effects

Common Side Effects:

Headache
Nausea
Vomiting
Constipation
Sweating
Insomnia
Pain
Peripheral edema
Drug withdrawal syndrome

Serious Side Effects:

Respiratory depression
Precipitated opioid withdrawal
Neonatal opioid withdrawal syndrome
Hepatotoxicity
Allergic reactions
Adrenal insufficiency
Hypotension
Serotonin syndrome

Drug Interactions

Buprenorphine-naloxone has important pharmacological interactions that require careful management.

Benzodiazepines (e.g., diazepam, alprazolam, clonazepam): Concurrent use with buprenorphine carries a serious risk of profound sedation, respiratory depression, coma, and death. If combined use is necessary, limit dose and duration, and monitor patients closely. An FDA boxed warning applies.
Other CNS depressants (e.g., alcohol, sedating antihistamines, gabapentin, pregabalin): Additive CNS depression increases the risk of fatal respiratory depression. Patients should be counseled to avoid alcohol and non-prescribed sedating substances.
CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, clarithromycin): May increase buprenorphine plasma levels, potentially intensifying both therapeutic and adverse effects. Monitor for excess sedation.
CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine): May reduce buprenorphine efficacy by accelerating its metabolism, potentially precipitating withdrawal symptoms or loss of therapeutic effect.
Full opioid agonists (e.g., morphine, oxycodone, heroin): Buprenorphine has a higher receptor binding affinity than most full agonists and may precipitate acute withdrawal if administered while a full agonist is still occupying receptors. Conversely, full agonists taken during buprenorphine maintenance may have blunted effects.

Additional Information

Buprenorphine/naloxone is a combination medication used for the treatment of opioid use disorder. This formulation combines buprenorphine (a partial opioid agonist) with naloxone (an opioid antagonist) to reduce the potential for misuse while providing effective treatment for opioid dependence.

Mechanism of Action

The combination works through complementary mechanisms. Buprenorphine is a partial mu-opioid receptor agonist that relieves cravings and withdrawal symptoms while producing a ceiling effect on respiratory depression. Naloxone is an opioid antagonist with poor sublingual/oral bioavailability (approximately 3%) but high parenteral bioavailability. When taken sublingually as directed, naloxone contributes minimally to the clinical effect because it is poorly absorbed. However, if the medication is dissolved and injected, naloxone becomes active and precipitates withdrawal, deterring intravenous misuse. This design helps ensure the medication is taken as prescribed.

Available Formulations

Buprenorphine/naloxone is available in several sublingual and buccal formulations. Sublingual tablets come in 2/0.5 mg and 8/2 mg strengths. Sublingual films are available in 2/0.5 mg, 4/1 mg, 8/2 mg, and 12/3 mg strengths. Generic formulations are available. The sublingual administration requires placing the medication under the tongue and allowing it to dissolve completely without chewing or swallowing.

Medical Uses

Buprenorphine/naloxone is FDA-approved for the treatment of opioid use disorder as part of a complete treatment plan that includes counseling and psychosocial support. It is used for both induction and maintenance therapy. The combination is preferred over buprenorphine alone in most cases due to its lower abuse potential. Clinical studies demonstrate that buprenorphine/naloxone significantly reduces illicit opioid use, improves treatment retention, and decreases opioid-related morbidity and mortality.

Dosing Guidelines

Treatment typically begins with induction when the patient is in mild to moderate opioid withdrawal (usually 12-24 hours after last short-acting opioid use or 24-72 hours after last long-acting opioid use). On day 1, a starting dose of 2/0.5 mg or 4/1 mg is given, with additional doses as needed up to 8/2 mg. On day 2, doses may increase to 16/4 mg. Maintenance doses typically range from 16/4 mg to 24/6 mg daily. Single daily dosing is standard, though some patients may benefit from divided doses. Precipitated withdrawal can occur if started too soon.

Important Safety Information

The medication carries a boxed warning regarding serious, life-threatening respiratory depression (especially with benzodiazepines or other CNS depressants), addiction/abuse/misuse potential, and neonatal opioid withdrawal syndrome. Patients should be instructed to keep the medication secure and away from children or others who may misuse it. Precipitated withdrawal occurs if administered before adequate withdrawal from full opioid agonists. Hepatotoxicity has been reported. Do not switch between buccal and sublingual products on a mg-per-mg basis due to different bioavailabilities.

Drug Interactions

CNS depressants (benzodiazepines, alcohol, other opioids, sedatives) significantly increase risk of respiratory depression and death. CYP3A4 inhibitors may increase buprenorphine levels; CYP3A4 inducers may decrease levels. Full opioid agonists will have diminished effect due to buprenorphine's high receptor affinity. Naltrexone blocks buprenorphine effects; a washout period is needed when switching. Serotonergic medications may increase serotonin syndrome risk.

Special Populations

For pregnant women with opioid use disorder, buprenorphine monotherapy (without naloxone) is generally preferred due to limited safety data on naloxone in pregnancy. However, some women may continue buprenorphine/naloxone if they were stable on it before pregnancy. Neonatal opioid withdrawal syndrome should be anticipated. The medication is excreted in breast milk; women on stable doses may breastfeed with monitoring. Safety in pediatric patients has not been established. Elderly patients may need lower doses. Use with caution in hepatic impairment.

Frequently Asked Questions

Naloxone is included as an abuse-deterrent. When the combination is taken sublingually as directed, naloxone is poorly absorbed and has minimal effect. However, if the product is dissolved and injected, naloxone becomes fully active and blocks opioid receptors, precipitating withdrawal in opioid-dependent individuals. This discourages misuse by injection.

Buprenorphine is a partial agonist with very high receptor affinity. If taken while full opioid agonists (such as heroin or oxycodone) are still bound to receptors, buprenorphine can displace them and provide less activation, triggering precipitated withdrawal — a rapid and intensely uncomfortable withdrawal syndrome. Waiting until you are in mild-to-moderate withdrawal ensures most receptors are unoccupied.

There is no universally correct duration. Many clinical guidelines recommend continuing medication for at least one to two years, and indefinite maintenance is appropriate for many patients, as it is associated with lower relapse rates and reduced overdose mortality. Discontinuation decisions should be individualized and made collaboratively with your prescriber.

Non-opioid analgesics (acetaminophen, NSAIDs) remain effective and are preferred for mild-to-moderate pain. For severe acute pain (e.g., after surgery), short-acting full agonist opioids may be needed at higher-than-usual doses because buprenorphine partially blocks opioid receptors. Pain management should always be coordinated between your buprenorphine prescriber and the treating physician.

At therapeutic doses, buprenorphine produces minimal euphoria — particularly once tolerance develops. Its partial agonist ceiling effect means that increasing the dose beyond a certain point does not produce additional opioid effects. Most patients report feeling "normal" rather than impaired, which is one of the treatment goals.

No. Medication-assisted treatment with buprenorphine-naloxone is evidence-based medicine that stabilizes brain chemistry, reduces cravings, and blocks the euphoric effects of other opioids. It significantly reduces the risk of overdose death, improves treatment retention, and allows patients to resume functional daily life. Major medical organizations recognize it as a first-line treatment for opioid use disorder.

Related Health Conditions

This medication is commonly used to treat or manage the following conditions:

Attention Deficit Hyperactivity Disorder (ADHD)

ADHD is a neurodevelopmental disorder marked by inattention, hyperactivity, and/or impulsivity, stemming from complex interactions between genetics, brain differences, and environmental factors, not poor parenting.

Learn More

Coronary Artery Disease (CAD)

Coronary Artery Disease (CAD) results from plaque buildup in coronary arteries (atherosclerosis), restricting blood flow and potentially causing angina, heart attack, or heart failure, influenced by factors like high blood pressure and cholesterol.

Learn More

Heart Failure Due to Coronary Artery Disease

Heart failure stemming from coronary artery disease arises from narrowed arteries restricting blood flow, weakening or stiffening the heart muscle and reducing its pumping efficiency.

Learn More

Medical Disclaimer: This information is for educational purposes only and should not be considered medical advice. Always consult with your healthcare provider before starting, stopping, or changing any medication. Your doctor can provide personalized recommendations based on your specific health condition and medical history.